Latham & Watkins advised Seres Therapeutics, while Mayer Brown represented Société des Produits Nestlé on the deal. Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advised scPharmaceuticals on the deal. scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
You must be a Standard 1 Year member to access this content.
Cravath, Swaine & Moore represented Illumina, Inc. on the transaction, and Latham & Watkins represented GRAIL, LLC. GRAIL, Inc. (NASDAQ: GRAL, formerly GRAIL, LLC), a healthcare...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advised Avidity Biosciences, Inc. on the offering, and Wilson Sonsini Goodrich & Rosati advised Avidity on patent matters related to the transaction. Cooley...
You must be a Standard 1 Year member to access this content.
Latham & Watkins and Wilson Sonsini Goodrich & Rosati advised Boundless Bio on the offering, and Cooley advised the underwriters. Boundless Bio, Inc. (Nasdaq: BOLD) a clinical...
You must be a Standard 1 Year member to access this content.
Kirkland & Ellis is advising Carlisle Companies Incorporated on the transaction, and Latham & Walkins is advising Amphenol Corporation. Amphenol Corporation (NYSE: APH), a leading global...
You must be a Standard 1 Year member to access this content.
Kirkland & Ellis advised AbbVie, Latham & Watkins advised Cerevel Therapeutics, Skadden advised Centerview partners LLC, as financial advisor to Cerevel Therapeutics in the transaction. AbbVie...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati and Latham & Watkins advised CARGO Therapeutics, Inc. on the offering, and Cooley advised the underwriters. CARGO Therapeutics, Inc. (CARGO) (Nasdaq:CRGX)...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP represents Vistagen in the offering. Vistagen Therapeutics, Inc. (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advised Neumora, and Cooley advised the underwriters. Neumora Therapeutics, Inc. announced the pricing of its initial public offering of 14,710,000 shares of its common...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advises e.l.f. Beauty in its acquisition of Naturium. e.l.f. Beauty (NYSE: ELF) has announced it has signed a definitive agreement to acquire Naturium,...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advises MindMed in growth financing with K2 HealthVentures. Mind Medicine Inc. (MindMed), a clinical stage biopharmaceutical company developing novel product candidates to treat...
You must be a Standard 1 Year member to access this content.
